Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03771417
Other study ID # 2018-026
Secondary ID R21AG058181
Status Completed
Phase N/A
First received
Last updated
Start date January 16, 2019
Est. completion date February 9, 2023

Study information

Verified date October 2023
Source Louisiana State University and A&M College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

What are the effects of resistance exercise (RE) alone or RE plus low intensity physical activity (LPA) breaks in sedentary time (ST) on skeletal muscle health in older adults? What are the effects of resistance exercise (RE) alone or RE plus low intensity physical activity (LPA) breaks in sedentary time (ST) on skeletal cardiometabolic health in older adults?


Description:

Although awareness of the detrimental impact that sedentary behavior has on skeletal muscle and cardiometabolic health has increased over the last 20 years, more than 60% of older adults remain sedentary for greater than 8 hours per day. Moreover, 80% to 90% of adults 60 years of age or older do not meet the current public health guidelines for aerobic exercise (AE) or resistance exercise (RE) based physical activity (PA). Collectively, these adverse health behaviors contribute to the development of multiple chronic medical conditions commonly afflicting older adults, including type 2 diabetes, cardiovascular disease, sarco/dynapenia, frailty, and premature mortality. Emerging evidence suggests that breaking up sedentary time with light intensity PA (LPA) improves muscle and cardiometabolic health. Recent data also suggest that RE combined with moderate intensity AE effectively improves muscle and cardiometabolic health in older adults. However, the impact that RE combined with LPA breaks in sedentary time has on muscle and cardiometabolic health in older adults remains unknown. The overall objective of this pilot study is to determine the effect of 16 weeks of RE alone or RE combined with LPA breaks in sedentary time on muscle and cardiometabolic health.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date February 9, 2023
Est. primary completion date February 9, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 80 Years
Eligibility Inclusion Criteria: 1. Are capable and willing to give written informed consent, and understand exclusion criteria 2. 65-80 years of age inclusive 3. Body Mass Index (BMI) between 18.5-34.9 kg/m2, inclusive 4. Physically inactive determined by self-report 5. Stable medical therapy for allowable medications for 30 days defined as: 1. No addition or removal of a medication 2. No change in dosage of a medication 6. Having no life-threatening conditions or diseases 7. Willing to allow researchers to use data, bio-specimens (blood and muscle tissue), and images (e.g., magnetic resonance imaging) for research purposes after study participation is completed 8. At least 2 weeks post-completion of the COVID19 vaccine regimen. a. Acceptable proof of vaccine includes a completed vaccine card and/or letter from a healthcare provider indicating the date that the COVID19 vaccine was completed. Exclusion Criteria: 1. Nursing home resident 2. Physically Active: a. > 100 min/wk of moderate OR > 50 min/wk vigorous intensity PA 3. Saint Louis University Mental State (SLUMS) score < 21 4. Evidence or self-report history of deep vein thrombosis, pulmonary embolism, cardiovascular, peripheral vascular, cerebral vascular, pulmonary, or renal disease 5. Evidence or self-report history of type 1 or 2 diabetes mellitus 6. Evidence or self-report history of a bleeding disorder 7. Evidence or self-report history of recurrent vasovagal episodes 8. Evidence or self-report history of severe depression, Schizophrenia, bipolar disease 9. Evidence or self-report history of mobility disability requiring a walker, wheel chair, or inability to walk across a small room. 10. Evidence or self-report history of orthopedic limitations that would preclude them from participation in a dynamic exercise program 11. Evidence or self-report history of severe arthritis (either osteoarthritis or rheumatoid arthritis) that would preclude them from participation in a dynamic exercise program 12. Evidence or self-report of history untreated thyroid dysfunction. 13. Weight loss of > 10% in the last 3 months prior to screening 14. History of weight loss surgery. 15. Use of medications known to influence study outcomes, such as: 1. Insulin 2. Oral antidiabetic medications (e.g., metformin) 3. Corticosteroids 4. Beta-blockers c. Anticoagulants 16. Allergy to lidocaine 17. Active smoking 18. Current consumption of > 14 alcoholic drinks per week based on self-report 19. Regular participation in resistance or aerobic exercise training within 3 months of initial screening 20. Absolute Contraindication to Exercise as Defined by the American College of Sports Medicine,16 including: 1. Resting diastolic blood pressure > 100 mm Hg 2. Resting systolic blood pressure > 180 mm Hg 3. Resting heart rate > 100 beats per min 21. Having a body weight greater than 440 pounds 22. Having medical implants such as a pacemaker or metal joint replacements 23. Having tattoos or permanent makeup completed <30 days prior to the visit 24. Recent (past 3 months) cancer diagnosis, undergoing immunotherapy, taking immune suppressants 25. Presence of allergies or infections requiring antibiotics within the past 14 days 26. Recent (past 3 months) major surgery on the abdomen, pelvis, or lower extremities 27. Any other condition that in the judgement of the Principal Investigator and/or the Medical Director of this protocol may interfere with study participation and adherence to the protocol. 28. Evidence or self-report history of severe depression in the last 5 years.

Study Design


Intervention

Behavioral:
Exercise Intervention
The use of exercise to improve muscle and cardiometabolic health in older adults.

Locations

Country Name City State
United States Lousiana State University Baton Rouge Louisiana
United States Pennington Biomedical Research Center Baton Rouge Louisiana

Sponsors (3)

Lead Sponsor Collaborator
Louisiana State University and A&M College National Institute on Aging (NIA), Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Skeletal Muscle Strength The investigators will determine the change from baseline in skeletal muscle strength. These measurements will be performed at baseline and following 16 weeks of exercise training using isokinetic dynamometry and 1 repetition maximum testing. Measured at week 0 (baseline) and week 16
Primary Skeletal Muscle Mass The investigators will determine the change from baseline in skeletal muscle mass. These measurements will be performed at baseline and following 16 weeks of exercise training using Dual X-Ray Absorptiometry and Magnetic Resonance Imaging. Measured at week 0 (baseline) and week 16
Secondary Mitochondrial Function The investigators will determine the change from baseline in mitochondrial function. These measurements will be performed at baseline and following 16 weeks of exercise training. Measured at week 0 (baseline) and week 16
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)